Foundayo for Menopause Weight Loss: New Oral GLP-1

What Is Foundayo (Orforglipron)?

Orforglipron is a non‑peptide GLP‑1 receptor agonist that’s taken as a once‑daily pill. It was recently FDA-approved for weight loss and marketed under the name Foundayo. Like other GLP-1 medications, it can support weight management, appetite regulation, and blood sugar control. 

NEW

Foundayo® Pill

Starting at $149

Daily tablet. No injections, fasting, or food restrictions. Average weight loss is 11.2% of body weight in 18 months.*

Start Now

GLP-1s have been hard to miss lately, so you’ve probably heard of the peptide options  like Ozempic® and Wegovy® (semaglutide) or Mounjaro® and Zepbound® (tirzepatide). Foundayo works similarly,  by activating GLP-1 receptors in the body—targeting the same appetite and metabolic pathways involved in hunger, fullness, and blood sugar regulation. But the way it's designed, and how it's taken, is different.

Unlike the peptide-based GLP-1 medications listed above, Foundayo is designed as a small molecule rather than a peptide. That allows it to be absorbed effectively as a pill while still activating the same GLP-1 pathways involved in appetite regulation and metabolism. 

It also means it can be taken with or without food, without some of the requirements associated with other oral GLP-1 medications (like Rybelsus® or Wegovy®  which need to be taken on an empty stomach). 

NEW

Wegovy® Pill

Starting at $149

Daily tablet. Average weight loss is 15% of body weight in 12 months*

Start Now

How GLP‑1 Medications Work in the Body

Even if you’re used to hearing the term GLP-1 almost daily in 2026, what these medications actually do isn't always obvious. Essentially, GLP-1—which is the abbreviation for glucagon-like peptide-1—is a naturally occurring hormone produced in the gut. It helps regulate appetite, digestion, and blood sugar levels.

These medications are designed to mimic or activate (depending on the specific medication) the same pathways as the body's natural GLP-1 hormone, helping reduce hunger and cravings while supporting blood sugar control.

They work in a few different ways:

• Sending fullness signals to the brain, which can reduce appetite and make it easier to eat less without feeling deprived

• Slowing stomach emptying, which helps meals feel more satisfying for longer and can make portion control easier

• Supporting insulin and glucose regulation, which plays an important role in metabolic health

GLP-1 medications are prescribed alongside healthy habits like regular exercise and balanced nutrition. Together, all these effects can support meaningful and sustainable weight loss over time. 

Potential Benefits for Women in Perimenopause and Menopause

Research shows that similar GLP-1 medications can support meaningful weight loss in women during perimenopause and menopause. And while weight loss is often the main reason people explore these medications, the potential benefits can extend beyond what you see on the scale.

That's particularly relevant during midlife, when hormonal changes can make weight management feel more challenging than it was previously  and contribute to increased fat storage around the abdomen.

Additional potential benefits include:

1. Support for healthier eating habits. By reducing hunger, cravings, and "food noise," GLP-1 medications can make it easier to stick to sustainable nutrition habits over time. This can then have tons of other positive ripple effects, like eating a more nutritious diet which supports other facets of health. 

2. Reduction in visceral fat. Weight that accumulates around the midsection during menopause is often visceral fat, which is associated with increased cardiometabolic risk. Losing some of this abdominal fat can support overall metabolic health.

3. Improved blood sugar regulation. GLP-1 medications help regulate insulin and glucose levels, which may be particularly beneficial for women with insulin resistance, prediabetes, or other metabolic risk factors.

4. Potential improvements in energy and quality of life. Some women report feeling more energetic as they lose weight and improve their metabolic health, which can make everyday activities and exercise feel more manageable. Exercise, a key component of weight management, is linked to many positive impacts on health, from cognitive and emotional to physical.

These benefits highlight why GLP-1 medications have become an important option for some women navigating the metabolic changes that often accompany menopause. 

How Oral GLP‑1 Pills Differ From Injectable Options

While both oral and injectable GLP-1 medications can support meaningful weight loss, there are some important differences between them:

Wegovy® Pen

Starting at $199 $499

Weekly injection. Average weight loss is 15% of body weight in 12 months*

Start Now

• The dosing schedule can differ. Most injectable GLP-1 medications, including semaglutide and tirzepatide, are taken once a week. Liraglutide is a daily injection. The oral GLP-1 medications currently available are taken daily.

• The form of medication can be a game-changer. Some patients are uncomfortable with injections (or simply don't want to add one to your routine),making an oral medication a more approachable and easier to stick with long term.

• Some injectable GLP-1s are dual-acting. Tirzepatide, the active ingredient in Zepbound and Mounjaro, targets both GLP-1 and GIP receptors, two hormone pathways involved in appetite and metabolic regulation. 

• Expected weight loss results can vary. All these differences are the reason treatment recommendations are often highly individualized. The research on orforglipron is still unfolding, but clinical trials show that women in perimenopause and post menopause lost an average of 14.4 percent of their body weight over 72 weeks. For context, another study found that tirzepatide led to an average weight loss of about 20 percent over 72 weeks, whereas Wegovy® led to an average weight loss of roughly 14 percent.

There isn't a single "best" option for everyone. The right choice depends on factors like your medical history, weight-loss goals, lifestyle, and personal preferences.

Side Effects and Safety Considerations from Foundayo

Foundayo (orforglipron) is generally considered safe when prescribed appropriately and monitored by a healthcare provider.

Like other medications that target the GLP-1 pathway, the most common side effects are gastrointestinal. They can include:

• Nausea

• Bloating

• Constipation

• Diarrhea

• Vomiting

Some people also report side effects such as headache, indigestion, or fatigue, particularly when first starting treatment or increasing their dose.

But on the bright side, studies on GLP-1s show that these symptoms are often temporary.  They’re usually most noticeable during the first few weeks of treatment or after a dose increase, and  gradually improve as the body adjusts. To help minimize side effects, healthcare providers typically follow a dose-escalation schedule, meaning the medication is increased gradually over time rather than all at once.

Because Foundayo is taken as a daily pill, consistency is super important. Taking it as prescribed and staying in contact with your healthcare provider can help you get the most out of treatment while also making it easier to manage side effects. 

Also, Foundayo is prescribed alongside a healthy diet and exercise. This should include getting plenty of protein and strength-training to prevent muscle loss (which can happen during significant weight loss).  Strength training large muscle groups can also help to boost metabolism and is especially important in perimenopause and menopause as estrogen decline impacts bone and muscle health

Also, as with any prescription medication, certain health conditions, medications, and personal risk factors may influence whether Foundayo is appropriate for you. A healthcare provider can review your medical history, discuss potential risks and benefits, and help determine whether it's a good fit for your weight management goals.

Who May Be a Good Candidate for Medication‑Based Weight Care

If you've been doing the right things—eating well, staying active, and getting enough sleep—but weight loss remains difficult or hard to sustain, a conversation with your healthcare provider about GLP-1 medications may be helpful. For many women, this conversation comes up during perimenopause and menopause, when hormonal changes can make weight management harder than it was earlier in life. 

Clinicians consider factors such as body weight, metabolic health, symptoms, medical conditions, and health history when evaluating whether medication-based weight care may be appropriate.  Research also suggests that long-term success is most likely when weight-loss medications are combined with a structured plan that includes nutrition, physical activity, and ongoing medical support.

Weight loss is only part of the journey. The ultimate goal is better health through an approach that's sustainable and fits your lifestyle. A healthcare provider can help determine whether medication-based weight care is right for you.

Recent Findings and Trending Efficacy Data for Foundayo

Now, how effective is Foundayo? There’s a growing body of data on Foundayo, and it’s one of the most notable recent developments in obesity medicine. 

For example, research presented at the 2026 American Diabetes Association (ADA) Scientific Sessions suggest that Foundayo may be particularly relevant for women navigating weight changes during midlife and menopause.

Let's dig a little deeper: 

In one major clinical trial program, women experienced significant weight loss across every stage of menopause—including premenopause, perimenopause, and postmenopause. At the highest dose of Foundayo, women in perimenopause lost an average of 14.4 percent of their body weight over 72 weeks, which translates to roughly 30 pounds for lots of the participants. And more than half of them achieved at least 15 percent total body weight loss.

NEW

Compounded Tirzepatide

Starting at $100

Weekly injection. Personalized dosing for gentler starts and individual goals**

Start Now

The results also showed meaningful reductions in waist circumference, with decreases of up to 4.9 inches. That's extra noteworthy during menopause, when hormonal changes can contribute to increased abdominal fat storage and make weight loss harder than it once was.

But beyond the weight loss results themselves, Foundayo is drawing attention because of its convenience. Unlike earlier oral GLP-1 medications that require fasting periods before eating or drinking, Foundayo is a non-peptide "small molecule" pill that can be taken with or without food and without water restrictions. For many women balancing work, caregiving, travel, and everything else life throws their way, that flexibility can make treatment easier to fit into a daily routine. 

NEW

Compounded Semaglutide

Starting at $70

Weekly injection. Personalized dosing for gentler starts and individual goals**

Start Now

One trial also highlights that Foundayo helps women maintain 75 to 80 percent of their weight loss when transitioning off injectable options. New research is also encouraging when it comes to heart health. People taking Foundayo with obesity or type 2 diabetes also had lower rates of major heart-related events.  This is another reminder that weight management can impact far more than what you see on the scale.

Feeling like your body is playing by a new set of rules during perimenopause or menopause? Chat with an Alloy clinician and discover weight management options designed for this stage of life. Regardless of which option you choose, we are here to help! 

Frequently Asked Questions

What is Foundayo and how does it differ from other GLP-1 medications?

Foundayo is a non-peptide GLP-1 receptor agonist that has been FDA-approved for weight loss as a once-daily pill. While famous peptide-based medications like Ozempic, Wegovy, Zepbound, and Mounjaro typically rely on weekly injections, Foundayo is engineered as a small molecule. This specific structure allows it to be swallowed as a tablet and absorbed effectively by the body. Crucially, it eliminates the rigid fasting guidelines tied to older oral options, meaning it can be taken with or without food or water restrictions.

What kind of weight loss results can women in menopause expect with Foundayo?

Clinical trial data highlighted at the 2026 American Diabetes Association Scientific Sessions shows that Foundayo is remarkably effective for midlife weight management. Perimenopausal women taking the highest dose lost an average of 14.4 percent of their body weight over a 72-week period, which translates to a loss of about 30 pounds for many individuals. Additionally, participants saw their waist circumference shrink by up to 4.9 inches, which is particularly beneficial since the hormonal drops in menopause frequently trigger stubborn abdominal and visceral fat storage.

What are the side effects of Foundayo and how are they managed?

The most frequent side effects of Foundayo are gastrointestinal, spanning nausea, bloating, constipation, diarrhea, and vomiting, alongside occasional headaches or fatigue. Because these symptoms are usually temporary and spike during the first few weeks or after a dose increase, doctors minimize the disruption by using a gradual dose-escalation schedule. To achieve the best health outcomes and maintain metabolic health, the daily pill should be paired with consistent nutrition, high protein intake, and regular strength-training to safeguard muscle mass during your weight loss journey.

SOURCES 

1. Allen JE, et al. (2026). Management of obesity in the menopause transition and postmenopausal period. https://www.soard.org/article/S1550-7289(26)00073-0/fulltext

2. Alper AD, et al. (2026). Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC12922244/

3. Aronne LO, et al. (2026). Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. https://pubmed.ncbi.nlm.nih.gov/42120723/

4. Aronne LO, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

5. Collins LO, et al. (2024). Glucagon-like peptide-1 receptor agonists. https://www.ncbi.nlm.nih.gov/books/NBK551568/

6. Foundayo. (2026). Orforglipron tablets for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf

7. Gorgojo-Martinez JU, et al. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: A multidisciplinary expert consensus. https://pubmed.ncbi.nlm.nih.gov/36614945/

8. Graczyk NI, et al. (2026). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity and symptoms in menopause: A review.  https://pmc.ncbi.nlm.nih.gov/articles/PMC12908505/

9. Holliday AD, et al. (2025). Appetite-related gut hormone responses to feeding across the life course. https://pmc.ncbi.nlm.nih.gov/articles/PMC11702868/

10. Janochova KA, et al. (2019). Visceral fat and insulin resistance - what we know?. https://pubmed.ncbi.nlm.nih.gov/30398218/

11. Lilly. (2026). Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause. https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-only-oral-glp-1-taken-without-food

12. Mikdachi HA, et al. (2025). GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. https://journals.lww.com/co-obgyn/abstract/2025/04000/glp_1_receptor_agonists_for_weight_loss_for.10.aspx

13. Mounjaro. (2022). Tirzepatide injection for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf

14. Nicolau JO,  et al. (2025). Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause. https://pubmed.ncbi.nlm.nih.gov/39761057/

15. Ozempic. (2017). Semaglutide injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf

16. Palacios SA, et al. (2024). Management of obesity in menopause. https://www.tandfonline.com/doi/10.1080/13697137.2024.2374760 

17. Rosenstock JU, et al. (2026). Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00202-3/abstract

18. Saxenda. (2010). Liraglutide injection for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf

19. Szeliga AN, et al. (2026). The impact of the menopausal transition on body composition and abdominal fat redistribution. https://pubmed.ncbi.nlm.nih.gov/41598677/

20. Wharton SE, et al. (2023). Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. https://pubmed.ncbi.nlm.nih.gov/37351564/ 

21. Wharton SE, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. https://pubmed.ncbi.nlm.nih.gov/34514682/